Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
van der Tuin SJ, Kühnast S, Berbée JF, Verschuren L, Pieterman EJ, Havekes LM, van der Hoorn JW, Rensen PC, Jukema JW, Princen HM, Willems van Dijk K, Wang Y.
van der Tuin SJ, et al. Among authors: berbee jf.
J Lipid Res. 2015 Nov;56(11):2085-93. doi: 10.1194/jlr.M057794. Epub 2015 Sep 4.
J Lipid Res. 2015.
PMID: 26342106
Free PMC article.